3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Ovarian Cancer Recurrent
2
Multiple Myeloma
2
Melanoma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Platinum-resistant Recurrent Ovarian Cancer
1
Platinum-resistant Ovarian Cancer
1
Peritoneal Neoplasms
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Lymphoma, Follicular
1
Lymphoma
1
Esophageal Squamous Cell Carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumor
1
Advanced Malignancies
1
Adenoviridae Infections
1
Interventions
Rituximab
90
Cyclophosphamide
30
Lenalidomide
28
Bendamustine Hydrochloride
24
Prednisone
20
Vincristine
19
obinutuzumab
17
Doxorubicin
16
fludarabine
14
ibrutinib
13
tazemetostat
9
idelalisib
9
Deoxycholic Acid
9
parsaclisib
8
Prednisolone
8
zanubrutinib
7
venetoclax
7
tofacitinib
7
tisagenlecleucel
5
pembrolizumab
5
ofatumumab
5
ibritumomab tiuxetan
5
duvelisib
5
Gemcitabine
5
Bortezomib
5
durvalumab
4
aflibercept
4
R-CHOP protocol
4
Methylprednisolone
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Follicular
×
1-dodecylpyridoxal
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled